Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)

China flag China · Delayed Price · Currency is CNY
11.25
+0.07 (0.63%)
Apr 30, 2026, 3:00 PM CST
-5.30%
Market Cap 4.55B
Revenue (ttm) 1.68B
Net Income (ttm) 48.72M
Shares Out 404.74M
EPS (ttm) 0.12
PE Ratio 96.19
Forward PE n/a
Dividend 0.34 (3.04%)
Ex-Dividend Date Jun 26, 2025
Volume 2,291,400
Average Volume 2,407,227
Open 11.12
Previous Close 11.18
Day's Range 11.11 - 11.30
52-Week Range 10.49 - 14.32
Beta 0.81
RSI 53.39
Earnings Date Apr 27, 2026

About SHA:603439

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China. [Read more]

Sector Healthcare
Founded 1995
Employees 2,852
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603439
Full Company Profile

Financial Performance

In 2025, SHA:603439's revenue was 1.70 billion, a decrease of -20.59% compared to the previous year's 2.14 billion. Earnings were 46.25 million, a decrease of -83.12%.

Financial Statements

News

There is no news available yet.